212 related articles for article (PubMed ID: 11779034)
1. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.
Zaveri N; Polgar WE; Olsen CM; Kelson AB; Grundt P; Lewis JW; Toll L
Eur J Pharmacol; 2001 Sep; 428(1):29-36. PubMed ID: 11779034
[TBL] [Abstract][Full Text] [Related]
2. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors.
Hawkinson JE; Acosta-Burruel M; Espitia SA
Eur J Pharmacol; 2000 Feb; 389(2-3):107-14. PubMed ID: 10688973
[TBL] [Abstract][Full Text] [Related]
3. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.
Fawzi AB; Zhang H; Weig B; Hawes B; Graziano MP
Eur J Pharmacol; 1997 Oct; 336(2-3):233-42. PubMed ID: 9384238
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Azuma T; Ichikawa D; Nambu H; Iguchi T; Iwasawa Y; Ohta H
Eur J Pharmacol; 2000 Aug; 402(1-2):45-53. PubMed ID: 10940356
[TBL] [Abstract][Full Text] [Related]
5. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.
Zaveri N
Life Sci; 2003 Jun; 73(6):663-78. PubMed ID: 12801588
[TBL] [Abstract][Full Text] [Related]
6. N-terminal modifications leading to peptide ORL1 partial agonists and antagonists.
Judd AK; Kaushanskaya A; Tuttle DJ; Sanchez A; Khroyan T; Polgar W; Toll L
J Pept Res; 2003 Nov; 62(5):191-8. PubMed ID: 14531842
[TBL] [Abstract][Full Text] [Related]
7. Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library.
Becker JA; Wallace A; Garzon A; Ingallinella P; Bianchi E; Cortese R; Simonin F; Kieffer BL; Pessi A
J Biol Chem; 1999 Sep; 274(39):27513-22. PubMed ID: 10488086
[TBL] [Abstract][Full Text] [Related]
8. Different domains of the ORL1 and kappa-opioid receptors are involved in recognition of nociceptin and dynorphin A.
Lapalu S; Moisand C; Butour JL; Mollereau C; Meunier JC
FEBS Lett; 1998 May; 427(2):296-300. PubMed ID: 9607332
[TBL] [Abstract][Full Text] [Related]
9. Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk.
Mandyam CD; Thakker DR; Christensen JL; Standifer KM
J Pharmacol Exp Ther; 2002 Aug; 302(2):502-9. PubMed ID: 12130708
[TBL] [Abstract][Full Text] [Related]
10. Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors.
Neal CR; Owens CE; Taylor LP; Hoversten MT; Akil H; Watson SJ
J Chem Neuroanat; 2003 Jul; 25(4):233-47. PubMed ID: 12842269
[TBL] [Abstract][Full Text] [Related]
11. In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated.
Ichikawa D; Ozaki S; Azuma T; Nambu H; Kawamoto H; Iwasawa Y; Takeshima H; Ohta H
Neuroreport; 2001 Jun; 12(8):1757-61. PubMed ID: 11409754
[TBL] [Abstract][Full Text] [Related]
12. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay.
Wnendt S; Krüger T; Janocha E; Hildebrandt D; Englberger W
Mol Pharmacol; 1999 Aug; 56(2):334-8. PubMed ID: 10419552
[TBL] [Abstract][Full Text] [Related]
13. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids.
Butour JL; Moisand C; Mazarguil H; Mollereau C; Meunier JC
Eur J Pharmacol; 1997 Feb; 321(1):97-103. PubMed ID: 9083791
[TBL] [Abstract][Full Text] [Related]
14. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.
Bloms-Funke P; Gillen C; Schuettler AJ; Wnendt S
Peptides; 2000 Jul; 21(7):1141-6. PubMed ID: 10998549
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity studies on high affinity NOP-active hexapeptides.
Judd AK; Tuttle DJ; Jones RW; Sanchez A; Polgar W; Berzetei-Gurske I; Toll L
J Pept Res; 2004 Sep; 64(3):87-94. PubMed ID: 15317498
[TBL] [Abstract][Full Text] [Related]
16. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
Sim LJ; Childers SR
J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
[TBL] [Abstract][Full Text] [Related]
17. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor.
Meunier JC
Eur J Pharmacol; 1997 Dec; 340(1):1-15. PubMed ID: 9527501
[TBL] [Abstract][Full Text] [Related]
18. Replacement of Gln280 by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids.
Mollereau C; Moisand C; Butour JL; Parmentier M; Meunier JC
FEBS Lett; 1996 Oct; 395(1):17-21. PubMed ID: 8849681
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of aminoalkylazetidines as ORL1 receptor ligands.
Wu WL; Caplen MA; Domalski MS; Zhang H; Fawzi A; Burnett DA
Bioorg Med Chem Lett; 2002 Nov; 12(21):3157-60. PubMed ID: 12372523
[TBL] [Abstract][Full Text] [Related]
20. Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.
Narita M; Mizoguchi H; Oji DE; Dun NJ; Hwang BH; Nagase H; Tseng LF
Br J Pharmacol; 1999 Nov; 128(6):1300-6. PubMed ID: 10578145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
